SureTrader SureTrader
Home > Boards > US OTC > Medical - Drugs >

ProtoKinetix, Inc. (PKTX)

PKTX RSS Feed
Add PKTX Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Past and present, acc724, PK holder
Search This Board:
Last Post: 9/28/2016 9:47:35 AM - Followers: 41 - Board type: Free - Posts Today: 1

      


CORPORATE OFFICE
9176 South Pleasants Highway
St. Marys, WV 26170
304-299-5070


CEO:
Clarence E. Smith

 
 


EMAIL: info@protokinetix.com 
OTCBB:PKTX

 


BUSINESS MODEL

ProtoKinetix is building value for investors through licensing and joint ventures with business partners, utilizing our internationally patented technology- which is comprised of a family of glycoprotein compounds - targeting biotechnology applications where existing and developing businesses have requirements that AAGPs™ - anti-aging glycopeptides - will dramatically improve.

The biotechnology business is often subject to expensive and time consuming regulatory processes. Our approach is to expedite the development of our technology primarily through business relationships that provide us with leading-edge technical and marketing expertise to expedite the time lines to place products on the shelf.

ProtoKinetix is not about building a business with "bricks and mortar." We believe there are so many AAGP™ applications that can best be reached through strategic business relationships.

We assess each opportunity with return on investment as the priority. Defining and measuring each agreement based upon corporate investment, time line to market, strength of the organization within a specific market segment and marketing strengths.

As we build the value of AAGP™ we are also taking steps to generate revenue through sales of products in markets that do not require regulatory oversight.

COMMERCIAL APPLICATIONS


Protokinetix AAGP™ research focuses on unique healthcare solutions that can provide cell survival which prolong the life of a cell, which is crucial in many medical research and procedures done today.

  1. Harvesting, storage and transplanting cells, tissues and organs.
    Treatments for conditions and disease caused by stress factors, including UV radiation, oxidation and inflammation

Acute medical research study is always progressing, but one of the problems that researchers rely on is the benefit from solutions that can deal with the fundamental factors of inflammation and oxidation. Both are well-known causes of life-threatening conditions and diseases, and accelerated aging. In addition many acute medical problems are benefiting from cell therapies and transplantation of cell, tissues and organs.

AAGP™ is now being used or investigated as a possible solution by many healthcare companies that specialize in medical cell therapies, organ transplant, trauma, blood product banking and anti-inflammation.

AAGP™ has taken Protokinetix's research team into preservation of stem cells and cell therapy, storage of blood platelets and blood products, harvesting and transplantation of islet cells for diabetes treatments, time sensitive organ transplantation and inflammation causing diseases and conditions.

Protokinetix expects to license several commercial applications from its AAGP™ family as well as expand its ongoing research and development with institutions and businesses. Protokinetix is actively in talks with several healthcare companies that are testing the molecule in their specific niche applications.
 

RECENT PR NEWS RELEASES..

ProtoKinetix’ 2nd Quarter Scientific Update....

           9:30 AM ET, 07/14/2016 - Business Wire

ST. MARYS, W. Va.--(BUSINESS WIRE)--Jul. 14, 2016-- (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:

The management team has been very busy since our last update. The following is a summary of our strategy and action in support of the Company’s direction.

Clinical Trial Application progress:

1. Method Development for toxicology studies that were conducted by ITR Laboratories Canada, Inc. (ITR).

2. Method Validation for toxicology studies to be conducted by ITR has commenced.

3. Molecular study for radiation stabilization has been completed by Iotron Industries Canada, Inc. (Iotron).

4. Bio Burden testing and Bio Burden Validation testing that was conducted by Nelson Laboratories, LLC (Nelson Labs) has been completed.

5. Certificate of Analysis for Drug Substance (GMP) for AAGP™ has been completed by Ambiopharm, Inc. (Ambiopharm).

6. AAGP™ has been shipped to Iotron to complete sterilization as required by the clinical trial protocols and returned to Ambiopharm.

7. A final report of pre-transplant AAGP™ treated islet cells analysis prepared by BRI Biopharmaceutical Research, Inc. (BRI).

8. We have completed the first draft of the Investigator’s Brochure (IB), a component of the clinical trial application to Health Canada. IB is a multidisciplinary document that summarizes the main elements of an entire development program to date. Although the IB also serves other purposes, it is written to enable investigators conducting clinical trial studies to assess the risks and benefits associated with an investigational product.

We are, at present, preparing a clinical trial application to Health Canada. This trial will be conducted by the Shapiro team at the University of Alberta on the well-established, Edmonton Protocol used for treatment of Type 1 Diabetes through islet cell transplants.

Neural Stem Cell Testing:

1. Testing on stem cells transplanted in retina tissue has been completed. This study was conducted at the University of British Columbia (UBC) and directed by Dr. Kevin Gregory-Evans. Stem cells tested with AAGP™ showed a 300% increase in engraftment survival over the control group.

2. The results of Dr. Gregory-Evans’ work were published in the Journal of Tissue Engineering and Regenerative Medicine, June 2016.

3. We have commenced a major study at UBC under the direction of Dr. Gregory-Evans for the effect of AAGP™ in the transplantation of human embryonic stem cells derived from neuronal type cells. This research holds significant potential for the treatment of conditions where neuronal cell death or damage has occurred. This includes age-related macular degeneration (AMD), stroke and spinal cord injury.

“I am extremely proud of how much we have accomplished in these last six months. I look forward to the future for this company that holds so much potential. I am grateful to all of those who have been involved in our progress.”-Mr. Clarence Smith.

We are looking forward to moving ahead with our application for clinical trials this year. We anticipate testing on the effects of AAGP™ on the preservation of whole donor organs and tissues for transplantation. We remain very confident in our strategy and appreciate your support of our actions to develop life-saving treatments for disease worldwide and to maximize financial returns to you, our stockholders and friends.

ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing the company is now preparing a submission to enter into a Phase 1/2 human clinical trial at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.


ProtoKinetix’ AAGP™ has been Published in the Journal of Tissue Engineering and Regenerative Medicine

                                                                                                                                               11:00 AM ET, 06/07/2016 - Business Wire

ST. MARYS, W.Va.--(BUSINESS WIRE)--Jun. 7, 2016-- ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP™ has been published in the Journal of Tissue Engineering and Regenerative Medicine and is available online at:

Anti-ageing glycoprotein promotes long-term survival of transplanted neurosensory precursor cells

AAGP™, an antifreeze glycopeptide, has been demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans.

ProtoKinetix has entered into a research agreement with the University of British Columbia to research neuronal cell transplantation as an extension of the studies recently published by Dr. Gregory-Evans in the Journal of Tissue Engineering and Regenerative Medicine.

Regarding the new studies, IN VIVO STUDIES TO DETERMINE THE POTENTIAL OF ANTI-AGING GLYCOPROTEIN (AAGP™) IN ENHANCING THE LONGTERM SURVIVAL OF NEURAL STEM CELLS, Dr. Gregory-Evans explains: “My research team at the University of British Columbia is very excited to move on to the next stage of our studies with ProtoKinetix’ compound AAGP™. We have shown that it is useful, in a simple model system, at promoting stem cell survival in tissue transplantation experiments. The next stage is now to move into animal model systems. This is for three reasons, first because it will give us a better quantitative understanding of AAGPs™ effectiveness, that is not only will it show us if AAGP™ works but also how well in might work in humans. Second, it will show us if there are any toxicity concerns in our target tissue (the central nervous system) and third as a regulatory requirement before undertaking human studies. Our major interest is blinding eye disease and stroke. We will study AAGP™ in models of both these common central nervous system ailments with the hope that, all going well, we can move on to early clinical studies in human sufferers within the next five years. Tissue transplantation promises to revolutionize the medicine of tomorrow and we think AAGP™ will be an important part of this revolution.”

ProtoKinetix is also pleased to report that it has received the assignment of the patents for the use of AAGP™ in retinal cell transplantation.

Journal of Tissue Engineering and Regenerative Medicine is a multidisciplinary journal that publishes research and reviews on the development of therapeutic approaches which combine stem/progenitor cells with biomaterials and scaffolds, and growth factors and other bioactive agents. The journal focuses on the development of biological functional substitutes that restore, maintain, or improve tissue or organ function. The publication carries an Impact Factor of 5.199.

ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing the company is now preparing a submission to enter into a Phase 1/2 human clinical trial at the University of Alberta. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.

AAGP™ Improves Results in Stem Cells Transplanted in Retina Tissue by 300%

 

10:41 AM ET, 05/02/2016 - Business Wire

ST. MARYS, W.Va.--(BUSINESS WIRE)--May 2, 2016-- ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that a paper submitted by Dr. Kevin Gregory-Evans on ProtoKinetix’ AAGP™ has been accepted by the Journal of Tissue Engineering and Regenerative Medicine for publication. The date of publication is unknown at this time but should be available online in advance of the printed version. AAGP™, an antifreeze glycopeptide, has been demonstrated to significantly improve the viable yield of stem cells transplanted in retinal tissue at the University of British Columbia under the guidance of Dr. Kevin Gregory-Evans.

Dr. Gregory-Evans concluded that embryonic cells treated with AAGP™ and transplanted into retina tissue, an accepted model for the central nervous system, compared to the control group not treated was 300% more viable.

Dr. Gregory-Evans proposes that AAGP™ works by inhibiting toxic signaling from surrounding necrotic tissue. Necrotic tissue is dead tissue, which usually results from an inadequate local blood supply. Necrotic tissue contains dead cells and debris that are a consequence of the fragmentation of dying cells.

”AAGP™ could be a huge benefit to the future of Pre-clinical and Clinical transplantation medicine,”said Dr. Kevin Gregory-Evans. He added,“AAGP™ will revolutionize transplantation medicine across the board.”

The significance of these results may have far reaching implications. In addition to cell, tissue and organ transplantations, there are strong implications that AAGP™ may have powerful applications for the treatment of stroke and heart attack treatment.

Dr. Kevin Gregory-Evans is currently Professor of Ophthalmology in the Faculty of Medicine, University of British Columbia, and holder of the Julia Levy BC Leadership Chair in Macular Research, Vancouver, Canada.

Dr. Gregory Evans' Bio is too extensive to repeat in full on this press release-his full Bio can be found at: http://protokinetix.com/about/kevin-gregory-evans/.

Journal of Tissue Engineering and Regenerative Medicine is a multidisciplinary journal that publishes research and reviews on the development of therapeutic approaches which combine stem/progenitor cells with biomaterials and scaffolds, and growth factors and other bioactive agents. The journal focuses on the development of biological functional substitutes that restore, maintain, or improve tissue or organ function. The publication carries an Impact Factor of 5.199.

ProtoKinetix, Incorporated is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance both engraftment and protection of transplanted cells used in regenerative medicine. Due to the results achieved over the last four years of testing the company is now preparing a submission to enter into a Phase 1/2 human clinical trial. Additional studies will be expanded to include whole organ transplantation and other cell therapies used in regenerative medicine.

ProtoKinetix Outlines Steps to Clinical Trial Application for AAGP™

9:00 AM ET, 04/26/2016 - Business Wire


ST. MARYS, W.Va.--(BUSINESS WIRE)--Apr. 26, 2016-- ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) outlines the steps to be completed for the application to conduct a clinical trial in Canada.

For the last four years ProtoKinetix has been involved in a collaboration with the Laboratory of Dr. James Shapiro, M.D., Ph.D., FRCSC, the director of the Clinical Islet Transplant Program at the University of Alberta Hospital. The outcome of these extensive tests resulted in a publication this February in the prestigious American Diabetes Association Journal, Diabetes and a planned submission to Health Canada of a clinical trial application (CTA). The CTA, for a Phase 1/2 study in patients, will involve the addition of AAGP™ to the well-established Edmonton Protocol for islet cell transplants for the treatment of type 1 diabetes.

Before a CTA can be submitted several rigorous tests and events have to be completed.

1. The molecule being tested has to be produced under current Good Manufacturing Practice (GMP) guidelines. GMP is an exacting standard of production that requires a validated and documented approach for each step of the process and a complete provenance for every component.

2. A Pharmacokinetic (PK) analysis with a validated methodology has to be completed on the molecule to determine AAGP™’s absorption and distribution throughout the human body.

3. The molecule has to be tested for toxicology, including evaluation of the genotoxic potential.

4. The end product must be certified as sterile.

5. An Investigator's Brochure has to be prepared incorporating these results as well as the Chemistry, Manufacturing, & Control (CMC) documentation provided by the GMP facility.

The CTA submission will be an Investigator-sponsored application from Dr. James Shapiro’s Laboratory.

In order to assist the Company in achieving a cost effective and timely CTA submission, ProtoKinetix has retained the services of the following experts and Contract Research Organizations (CROs):

Evelina Rubinchik PhD

Dr. Rubinchik is our contracted toxicologist who is organizing theselection of nonclinical CROs and management of toxicological studies. Dr. Rubinchik is also involved in the preparation of project budgets and timelines, review, and interpretation of toxicological data.

Dana Nohynek MSc, RAC

Ms. Nohynek is an independent regulatory consultant with expertise in Clinical Trial Application submissions and liaising with the Canadian regulatory authority.

PK Analysis CRO

BRI Biopharmaceutical Research Inc. is a specialized analytical, LC/MS/MS bioanalytical and DM/PK contract research organization (CRO) servicing pharmaceutical and biotechnology companies in discovery, preclinical and clinical programs supporting IND and Toxicology CROs.

Toxicology CRO

ITR Canada Inc. is an international contract research organization that provides non-clinical toxicology services for the biotechnology and pharmaceutical industries with clients located around the globe. Operating in Montréal since 1989, ITR’s purpose-built preclinical research facility was designed to be optimized for quality technical and scientific research. A privately-held organization with more than 300 employees in Canada, ITR offers personalized services from planning and study program design to study implementation and reporting for regulatory drug filing. ITR Canada is CCAC and AAALAC accredited, and studies conducted are fully compliant with GLP.

Manufacturing CRO

AmbioPharm, Inc. (APi) is a full-service peptide manufacturing company headquartered in North Augusta, SC, USA. In its cGMP manufacturing facilities in the USA and Shanghai, China, it develops highly efficient processes for manufacturing peptides at small to very large scale as Active Pharmaceutical Ingredients used in New Chemical Entities and generic peptides by clients worldwide. 

ProtoKinetix Corporate Update..

Jan. 5, 2016
 

ST. MARYS, W. Va.--(BUSINESS WIRE)--Jan. 5, 2016-- ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to provide the following corporate update to its stockholders:

Fiscal 2015 was a year of significant progress for ProtoKinetix, Incorporated. We executed several complex initiatives and continued to make great strides in delivering the strategic initiatives to improve the fiscal health of the Company and to further the scientific advancement of the AAGP™ molecule. Overall, the company’s regulatory status, financial position and scientific foundation for commercial growth are all stronger today than they were a year ago.

Our company has recently been restructured to improve efficiency and to enable growth and value to our stockholders. We have a new management team comprised of some old and some new faces. The team members are:

Clarence E. Smith President and CEO

Susan M. Woodward, CFO

Edward P. McDonough, Director and Head of Audit Committee

Peter Jensen, Head Consultant Business Advisory Board

Julia Levy, Head Consultant Scientific Board

Grant Young, Head Consultant Research and Development

The financial position of ProtoKinetix has never been stronger. Since June of 2014 all past overdue filings with the Securities Exchange Commission have been brought up to date. We received a Full Revocation Order on February 23, 2015 from the British Columbia Securities Commission in regards to its previously implemented Cease Trade Order issued on May 9, 2013. During this time period, ProtoKinetix negotiated a debt settlement with Standard Bankcorp resulting in a gain on settlement of $192,000.

All US tax returns have been filed from 1999 to 2014 and ProtoKinetix has been accepted to both the Offshore Voluntary Disclosure Program and the Domestic Voluntary Disclosure Program to comply with US tax law.

As of June 8th, ProtoKinetix began trading on the OTCQB® Venture Marketplace under the symbol "PKTX." The Company was formerly trading on the OTC Pink® marketplace under the same symbol.

We were pleased to acquire a portion of certain patents and all rights associated therewith from the University of Alberta pursuant to a Royalty Agreement entered into on or about April 8, 2015.

ProtoKinetix has had positive changes to our Balance Sheet as follows:

 

Account

   

Balance

12/31/14

   

ProjectedBalance12/31/15

   

 

Change

Cash     317     360,000     359,683
Debt     818,143     135,000     (683,143)
Shares     175,662,433     216,602,433     40,940,000
Assets           65,000     65,000

Our cash position increased by $359,683 due to an increase in private placements. Debt decreased by $683,143 due to settlement of all long and short term debts. We issued 40,940,000 shares of our common stock in connection with private placements, consulting agreements and settlement of debt. Assets increased by $65,000 due to the acquisition of patents.

Our CFO, Susan M. Woodward noted, “During this current year we have made great strides in placing ProtoKinetix to be in a much more favorable position to allow the Company to move forward and keep stride with the blossoming scientific advances of our AAGP™ molecule. I look forward to our continued success in 2016 with the support of our current and future stockholders as well as the dedication of our management and consulting team.”

This year ProtoKinetix had notable achievements of which we are very proud. AAGP™ was presented at the Congress of the International Pancreas and Islet Transplant Association in Melbourne, Australia in November. We also completed an intense, 3-year islet transplantation study with the University of Alberta. Currently, we have completed a peer review and have been published in the prestigious, American Diabetes Association’s Journal: Diabetes. We are continuing to study the effects of AAGP™ on Non-Obese Diabetic mice at the Dr. James Shapiro Lab in Edmonton at the University of Alberta.

We are, at present, preparing a clinical trial application to Health Canada. This trial will be conducted by the Shapiro team at the University of Alberta on the well-established, Edmonton Protocol used for treatment of Type 1 Diabetes through islet cell transplants.

As part of this submission, the company has:

Commissioned AmbioPharm, Inc. to produce AAGP™ under strict GMP (Good Manufacturing Practice) standards. GMP is required by Health Canada and US FDA (United States Food and Drug Administration) for human use. Toxicity testing will be conducted by a third party. Pharmacokinetics and Pharmacodynamics (PK/PD) has been addressed by BRI Labs in Vancouver. PK/PD studies the absorption rate and quantities of drugs through the human body.

We are looking forward to moving ahead with our application for clinical trials in the coming year. We anticipate testing on the effects of this molecule on the preservation of whole donor organs and tissues for transplantation.

In closing, I want to thank our Board of Directors, the Business and Scientific Advisory Board and the rest of the ProtoKinetix team, whose creativity, hard work and dedication have made this year’s achievements possible. Our strong relationship with Dr. James Shapiro and his scientific team continues to be a key asset in following our path to commercialization. We have a unique opportunity to make a difference and we are well prepared to meet our corporate needs for 2016 and pursue continued growth and maximize stockholder value.

AAGP Found to Significantly Improve Islet Cell Transplantation in Type 1 Diabetes Patients

Ticker Symbol: U:PKTX

Dec 17, 2015

ST. MARYS, W. Va. -- (Business Wire) --

ProtoKinetix, Incorporated (OTCQB:PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that their molecule, AAGP, an antifreeze glycopeptide that mimics a naturally occurring glycoprotein found in Arctic fish is helping to significantly improve the efficacy of Cell Transplant Treatments for diabetes - a procedure that transplants insulin producing islet to render them insulin independent for periods of time.

Anti-Aging GlycoPeptide (AAGP), is the focus of a new study published in the journal Diabetes. Researchers from the University of Alberta's Faculty of Medicine & Dentistry found that by soaking islet cells in AAGP for an hour and then washing it off prior to transplantation, the cells were protected from tacrolimus an antirejection drug commonly used during transplants that is toxic to islets cells.  

Normally when we expose human islets to tacrolimus in the petri dish, they flat line and don?t release insulin at all, says James Shapiro, senior author of the study and Canada Research Chair in Transplant Surgery and Regenerative Medicine at the U of A. When we add the AAGP and wash it all off, the cells work perfectly normally, and are protected in a remarkably durable manner. We find we need far fewer cells to treat diabetes in our preclinical models than we would normally. 

Since his creation of the Edmonton Protocol in 1999, more than 250 patients have been treated by Shapiro through islet cell transplantation. A key challenge of the procedure though is that most patients typically need two islet infusions, each prepared from a separate pancreas organ donor. Shapiro says there aren't enough organ donors to meet demand. Through the use AAGP, a greater number of islet cells will survive the procedure, potentially allowing more patients to be treated.  

Just a one hour soak in AAGP is enough to protect the islet cells for up to a month or two afterwards. It has a very potent and profound effect, says Shapiro. As a direct result of these findings, we're now moving forward with plans for a first in human clinical trial?led at the University of Alberta?testing this drug in our human islet cell transplant program.? 

This synthetic molecule seems to provide significant protection to cells exposed to multiple deleterious conditions, such as UV radiation, starvation, extreme temperatures andoxidative stress, says Boris Gala-Lopez, lead author of the study and a clinical/research fellow at the U of A's Department of Surgery. We are certainly very excited for the multiple opportunities this finding entails to the field of transplantation research. 

Funding for the study was provided by the Diabetes Research Institute Foundation of Canada, while the drug AAGP was provided by ProtoKinetix.  

We are very excited to have our AAGP molecule showcased in this prestigious journal. We are also extremely confident in the ongoing success of our collaboration with Dr. James Shapiro and his outstanding team said Clarence Smith, President and Chairman of ProtoKinetix.

If proven successful in human clinical trials, Shapiro believes the inclusion of AAGP could soon become a permanent addition to the Edmonton Protocol representing a significant step forward in the treatment of Type 1 diabetes through islet transplantation. While more research is needed, he also believes the drug shows promise for a wide range of transplantations?potentially working to protect organs as effectively as it protects islets. 


ProtoKinetix’ AAGP™ to Be Presented at the Congress of the International Pancreas and Islet Transplant Association

9:00 AM ET, 09/10/2015 - Business Wire

ST. MARYS, W. Va.--(BUSINESS WIRE)--Sep. 10, 2015-- ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that AAGP™ will be presented at the 2015 Joint Congress of the IPITA-IXA-CTS onMonday, November 16, 2015.The Joint Congress of the International Pancreas and Islet Transplant Association (IPITA), the International Xenotransplantation Association (IXA) and the Cell Transplant Society (CTS) to be held in Melbourne, Australia, 15–19 November 2015.

Dr. Boris L. Gala-Lopez, Research Fellow of Department of Surgery in the Alberta Diabetes Institute at the University of Alberta will be giving a lecture titled “Anti-aging Glycopeptide Protects Human Islets Against Tacrolimus-related Injury and Facilitates Engraftment” to support his conclusion that, “Supplementation with AAGP™ during the culture period improves islet quality and potency. Upon transplantation, pre-treatment with AAGP™ may facilitate engraftment in mice, improve graft secretory function and may attenuate long-term tacrolimus induced graft dysfunction. These findings may constitute a clear opportunity to develop more efficient strategies against post-transplant diabetes mellitus.”

For details see the web site: confman.melbourne2015.org/mobis/lecture/758

About Dr. Boris L. Gala-Lopez

Dr. Gala-Lopez is currently a PhD Research Fellow in the Clinical Islet Transplant Program at the University of Alberta. He has been responsible for multiple preclinical and clinical investigations in the field of islet transplantation to improve the novel treatment for Type 1 diabetes mellitus.

Dr. Gala-Lopez has also done extensive work in the area of ischemia-reperfusion injury for cell and solid organ transplantation.

ProtoKinetix Begins Testing Diabetic Mice with AAGP™ at the University of Alberta..

10:00 AM ET, 09/18/2015 - Business Wire

ST. MARYS, W. Va.--(BUSINESS WIRE)--Sep. 18, 2015-- ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that it has begun testing NOD (Non Obese Diabetic) mice with its AAGP™ molecule at the James Shapiro laboratory at the University of Alberta.

Type 1, diabetic NOD mice with AAGP™ versus a control group of Type 1, diabetic NOD mice without AAGP™ will be monitored for their blood-glucose levels. Using the NOD mice as a model the Edmonton team will be specifically assessing the potentially protective effect of AAGP™ against the antibody attack conducted against the islet cells in the pancreas.

NOD Mice, like the Bio-Breeding rat, are used as an animal model for Type 1 diabetes. Non-obese diabetic (NOD) mice exhibit a susceptibility to spontaneous development of autoimmune insulin dependent diabetes mellitus (IDDM).The NOD strain and related strains were developed at Shionogi Research Laboratories in Aburahi, Japan by Makino and colleagues and first reported in 1980.The group developed the NOD strain by an outbreeding of the cataract-prone strain from JcI:ICR mice.

At the conclusion of these tests, the internal organs of the NOD mice will be examined for any evidence of toxicity and bioavailability. This data is an extremely valuable step on the critical path towards submissions to Health Canada or the FDA for human clinical trial applications.

About the James Shapiro Laboratory

The James Shapiro Laboratory is active experimental laboratory working on improving long term survival of transplanted islets, and in immunomodulation of transplanted tissues. He is Principal Investigator on several NIH and JDRF-funded clinical trials, including clinical testing of costimulation blockade in islet transplantation.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release may contain statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.



View source version on businesswire.com: http://www.businesswire.com/news/home/20150918005068/en/

Source: ProtoKinetix, Inc.

ProtoKinetix, Inc.Clarence E. Smith, President & Chief Executive Officer304-299-5070csmith@protokinetix.com

 

***PKTX...ProtoKinetix Reports on Its Strong Collaboration with the James Shapiro Laboratory at the University of Alberta


St. Marys, West Virginia, August 4, 2015

***ProtoKinetix, Incorporated (OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to report on its collaboration with the James Shapiro laboratory at the University of Alberta. The sole intention of the collaboration is to develop a commercial product pipeline of therapeutic applications for the AAGP™ family of molecules.

...Professor James Shapiro is Professor of Surgery, Medicine and Surgical Oncology, and Director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Program at the University of Alberta in Edmonton, Canada. He has a busy hepatobiliary surgical practice in HPB oncology, and in liver and kidney-pancreas transplant surgery. His center carries out 80 liver transplants per year, and has done around 80 living donor liver transplants. The University of Alberta just celebrated their 1000th liver transplant.

...Dr. Shapiro directs the largest clinical islet transplant program worldwide with almost 170 patients treated, and led the clinical team that developed the "Edmonton Protocol" - the first trial to achieve consistent 100% insulin independence in a series of islet-alone transplant recipients with Type 1 diabetes (published in the NEJM 2000). Before Dr. Shapiro’s trial, the success rate with islet transplantation was less than 8%. He led an international multicenter trial to replicate these findings in 9 international centers (published in NEJM 2006).

...Over the last 32 months Dr. Shapiro and his team have been extensively testing the AAGP™ molecule in allogeneic transplants using human islet cells as the model. As regenerative medicine is rapidly becoming adopted in the treatment of degenerative diseases, the protection of the transplanted cells, tissues, and organs is of paramount importance. Transplanted cells and tissues are subjected to extreme stress factors that, unless protected, could cause failure to graft or premature death. The success of the tests conducted in Edmonton have demonstrated that AAGP™ has the potential to be widely adopted in many areas of regenerative medicine.

.."I'm very excited about our ongoing collaborations with PKTX and by the remarkable potency of AAGP. This molecule has great potential, and we are just beginning to scratch beneath the surface," said Dr. James Shapiro.

...As a result of the tests, Dr. Shapiro and his team are developing further testing based on three primary activities:

..1. The ongoing testing and refinement of cellular transplantation using human islet cells as the demonstrated model. In particular, AAGP™ may provide powerful protection against hostile agents that severely inhibit engraftment success. Cell therapies are currently being developed around the world for the treatment of spinal cord injury, damaged heart tissue, stroke, diabetes as well as many other conditions.

..2. Human organ preservation. The program will assess the effect of AAGP™ in extending the transplant viability of donor organs. The Canadian National Transplant Research Program is a major national initiative involving the Federal institutes of health, all Provinces and the private sector. http://www.cntrp.ca/. The first testing will be conducted on livers to determine whether AAGP™ can extend the ex-vivo functionality of the organ.

..3. Auto immune disease. This class of diseases occur where the body's immune system starts to attack healthy cells. Diseases in this category include, rheumatoid arthritis, multiple sclerosis and Type 1 diabetes. Using the NOD (Non Obese Diabetic) mice as a model the Edmonton team will be specifically assessing the potentially protective effect of AAGP™ against the antibody attack conducted against the islet cells in the pancreas.

...“This impressive team of transplant surgeons and scientists have made clear to us the dramatic scope of applications that our family of molecules possesses,” said Clarence Smith, President, CEO and Chairman of the Board of ProtoKinetix.

.....About the James Shapiro Laboratory

The James Shapiro Laboratory is active experimental laboratory working on improving long term survival of transplanted islets, and in immunomodulation of transplanted tissues. He is Principal Investigator on several NIH and JDRF-funded clinical trials, including clinical testing of costimulation blockade in islet transplantation.

 


**PKTX.. ProtoKinetix Upgrades to OTCQB... OFF of Pinks..!   


ST. MARYS, W.Va., June 8, 2015 /PRNewswire/ -- ProtoKinetix, Incorporated (OTCQB: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that ProtoKinetix began trading today on the OTCQB(R) Venture Marketplace under the symbol "PKTX." The Company was formerly trading on the OTC Pink(R) marketplace under the same symbol.
U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the Company at: http://www.otcmarkets.com/stock/PKTX/quote.

"After considerable effort and significant investment in our public disclosure, we are proud to be trading on the OTCQB marketplace. This upgrade should broaden our shareholder base, improve liquidity and increase the visibility for our achievements going forward," said Clarence E. Smith, President and Chief Executive Officer of ProtoKinetix.

The OTCQB Venture Marketplace offers transparent trading in entrepreneurial and development stage U.S. and international companies. To be eligible, companies must be current in their financial reporting and must undergo an annual verification and management certification process. Companies must also meet a minimum one penny bid test and may not be in bankruptcy.

About ProtoKinetix

ProtoKinetix, Inc. (OTCQB: PKTX) is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP(TM)) that enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP(TM) molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company's filings with the Securities and Exchange Commission.

Clarence E. Smith -- President and CEO

 

**PKTX..CEO Clarence Smith Reports on Edmonton Meetings with Dr. James Shapiro and his Team...

9:30 AM ET, 06/05/2015 - Business Wire

ST. MARYS, W.Va.--(BUSINESS WIRE)--Jun. 5, 2015-- ProtoKinetix, Incorporated(OTC: PKTX) (the "Company" or "ProtoKinetix") (www.protokinetix.com) is pleased to announce that CEO Clarence Smith recently returned from visiting Dr. James Shapiro at the University of Alberta. Mr. Smith met with Dr. Shapiro and his impressive team, including Dr. Boris Gala-Lopez. As previously announced, the Company has been heavily involved with the James Shapiro Laboratory for the last 24-months. Dr. Shapiro’s team has conducted extensive tests on islet cell transplantation using the AAGP™ molecule for the treatment of diabetes using AAGP™. Mr. Smith was impressed with the program and gratified that AAGP™ was proving to be a central element in the research.

Dr. Shapiro is a professor of surgery, medicine and surgical oncology. He is director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Programs at the University of Alberta. He is also principal investigator of National Institute of Health and the Juvenile Diabetes Research Foundation clinical trials. In addition to these positions, he is the leader of the Project 1 - Ex-vivo Organ Transplant Protection and Repair Program of the Canadian National Transplant Research Program.

Due to the excellent results of these tests on islet cell transplantation with AAGP™, Dr. Shapiro and his team are expanding their field of investigation to include:

1) Whole Organ Preservation

a. A major initiative of the Canadian National Transplant Research Program (CNTRP).

b. Preservation of hearts, lungs, kidneys, livers and transplantable tissue has become of critical importance to transplantation medicine.

2) Non Obese Diabetes (NOD) Mice

a. NOD mice are used as an animal model for Type 1 Diabetes testing.

b. Dr. Shapiro’s team shall be exploring the potential of AAGP™ to delay the progression of this disease.

“This impressive team of transplant surgeons and scientists have made clear to me the dramatic scope of applications that our family of molecules possess,” said Clarence E. Smith, President and Chief Executive Officer.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150605005032/en/

Source: ProtoKinetix, Inc.

ProtoKinetix, Inc.Clarence E. Smith, 304-299-5070President and CEO

 

***University of Alberta...Acquisition of Patent....

***ProtoKinetix Announces Acquisition of Patents  12:26 PM ET, 04/14/2015 - Business Wire

ST. MARYS, W. Va.--(BUSINESS WIRE)--Apr. 14, 2015-- ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) (“ProtoKinetix” or the “Company”) is pleased to announce that it has completed the acquisition of a portion of certain patents and all rights associated therewith (the “Patent Rights”) from the University of Alberta (“UAB”) pursuant to a Royalty Agreement (the “Agreement”) entered into on or about April 8, 2015.

The Agreement also grants UAB a royalty of 5% of the gross revenue from the assignment, manufacturing, sale, distribution, or licensing of the Patent Rights and any commercial products generated from the Patent Rights. The Company has the irrevocable option to purchase the royalty for CAN $5,000,000 (approximately US $4,000,000) for two years from the earlier of the first date UAB publishes its research related to the Patent Rights or September 1, 2015.

Through this assignment, the Company has gained UAB’s portion of US provisional patent application no. 62/007,626 related to the use of anti-aging glycopeptides to enhance beta cell health, survival and improve transplant outcomes, and all patents issuing from and claiming priority to such application.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

Cautionary Statement Regarding Forward-Looking Information

Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law, including statements regarding the Company's intention to license the Patent rights to third parties and the potential treatments for which the Company's AAGPTM may be applied. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements.The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements.More detailed information about potential factors that could affect financial results is included in the documents filed by the Company from time to time with the United States Securities Commission and with securities regulatory authorities in Canadian on SEDAR.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Clarence E. Smith –President and CEO

Source: ProtoKinetix, Inc.

ProtoKinetix, Inc.Clarence E. Smith, President & Chief Executive Officer304-299-5070csmith@protokinetix.com

 

 ***ProtoKinetix Announces Acquisition of Patents

ST. MARYS, W. Va.--(BUSINESS WIRE)--Apr. 7, 2015-- ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) (“ProtoKinetix” or the “Company”) is pleased to announce that it has completed the acquisition of certain patents and all rights associated therewith (the “Patents”) from Institut National des Sciences Appliquées de Rouen (“INSA”) pursuant to an Assignment of Patents and Patent Application (the “Patent Assignment”) entered into on or about January 5, 2015.

ProtoKinetix made payment of 25,000 Euros to INSA for all of the Patents and rights associated therewith, for the “Gem difluorinated C-glycopeptides, their preparation and their use for the preservation of biological materials and/or in cryosurgery” family of patents, which includes issued patents in Canada (Patent No. CA2,558,801), England, France, and Germany (Patent No. EP1,817,329) and the United-States (Patent No. US8,394,362). These Patents secure, amongst other things, key intellectual property rights to the Company’s AAGP™ lead compound.

By securing these Patents, the Company is in a better position to move forward with its operations. “We are pleased to secure the rights to these Patents as we can now license the rights to other companies to develop different applications of the AAGP™ lead compound,” said Clarence E. Smith, President and Chief Executive Officer.

About ProtoKinetix

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

Cautionary Statement Regarding Forward-Looking Information

Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law, including statements regarding the Company's intention to license the Patent rights to third parties and the potential treatments for which the Company's AAGPTM may be applied. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements.The Company undertakes no obligation to update forward-looking information if circumstances or management’s estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements.More detailed information about potential factors that could affect financial results is included in the documents filed by the Company from time to time with the United States Securities Commission and with securities regulatory authorities in Canadian on SEDAR.

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

Clarence E. Smith –President and CEO
Source: ProtoKinetix, Inc.

ProtoKinetix, Inc.Clarence E. Smith, President & Chief Executive Officer304-299-5070csmith@protokinetix.com

 


***University of Alberta Diabetes Institute Encouraged by Preliminary Results of Testing of ProtoKinetix Licensed AAGP™ Molecule in Islet Cell Transplantation


ST. MARYS, W. Va.--(BUSINESS WIRE)--Mar. 26, 2015-- ProtoKinetix (OTC: PKTX) (www.protokinetix.com) is pleased to be able to report a comprehensive transplantation testing program being conducted for the last two years in conjunction with the University of Alberta transplant research team. The Company is collaborating with the James Shapiro Laboratory at the University of Alberta in Edmonton, Alberta. Dr. Shapiro directs the largest clinical islet transplantation program in the world.

Dr. Shapiro is a professor of surgery, medicine and surgical oncology. He is director of the Clinical Islet Transplant Program and the Living Donor Liver Transplant Programs at the University of Alberta. He is also principal investigator of National Institute of Health and the Juvenile Diabetes Research Foundation clinical trials. In addition to these positions, he is the leader of the Project 1 - Ex-vivo Organ Transplant Protection and Repair Program of the Canadian National Transplant Research Program.

During the last 24-months, Dr. Shapiro’s Ph.D. student, Dr Boris Gala-Lopez, and his team have conducted extensive testing with our AAGP™ molecule using human islet cells in transplantation, investigating its effect on engraftment, insulin production, protective effect against anti-rejection drugs and investigation of the mechanism of action. The results provided consistent encouragement to continue testing to develop protocols that can be applied to transplantation medicine.

Allogeneic transplantation is the transplanting of cells, tissues or organs from the same species, but not with the host DNA. Serious issues that have to be addressed are the engraftment of the transplanted organ or cells and the subsequent protection against the immune response. The protection, in the form of anti-rejection drugs, is toxic and causes damage to the graft. AAGP™ has been shown in these trials to increase engraftment and reduce the toxicity damage.

Dr. Shapiro says “We are all very encouraged by the early results of these studies, and I look forward to working with the Company in moving toward use of AAGP™ in future clinical applications”.

 

                                                                                                              

                                   ****Dr. Julia Levy Accepts Position on ProtoKinetix’ Business and Scientific Advisory Board 

 

    VANCOUVER, British Columbia--(BUSINESS WIRE)--Feb. 26, 2015-- ProtoKinetix (OTCQB:PKTX) (www.protokinetix.com) is pleased to announce that Julia Levy, PhD, co-founder of QLT, Inc., has accepted the position as head of its Business and Scientific Advisory Board. 

Discoveries made by her and colleagues at the University of British Columbia in the field of photodynamic therapy were the basis of the first medical treatment of macular degeneration, a leading cause of blindness among the elderly, a treatment was developed by QLT, Inc. She served first as Chief Scientific Officer and later as Chief Executive Officer of QLT. Dr. Levy is an officer of the Order of Canada and has received a number of honorary degrees. She has served on the boards of a number of companies as well as of charitable organizations. 

As ProtoKinetix continues to grow and to make the important transition to becoming a full-fledged clinical stage company, Dr. Levy’s in-depth experience and understanding of both the regulatory and business aspects of the biopharmaceutical industry are particularly valuable for the expansion and commercialization of AAGP™ applications

About Dr. Levy 

As co-inventor of Visudyne and co-founder of QLT, Dr. Levy served in several key senior positions at the company including Chief Scientific Officer as well as President and CEO. Under Dr. Levy’s leadership, QLT recorded the strongest period of growth in the company’s history and earned a reputation for achieving milestones, including FDA approval for Visudyne to treat age-related macular degeneration, the commonest cause of severe vision loss in the elderly. Dr. Levy has earned numerous awards and honours including an appointment as an Officer of the Order of Canada, the Female Entrepreneur of the Year for International Business, Pacific Canada Entrepreneur of the Year and the Future of Vision Award from the Foundation Fighting Blindness. In 2002 she received, along with Dr. David Dolphin, the Friesen-Rygiel prize for medical research and the Prix Galien Canada research award. In her honour, the Julia G. Levy Professorship in Ophthalmology Chair was created at Johns Hopkins Hospital Wilmer Eye Institute in 2004, the same year she was awarded the Lifetime Achievement Award from the BC Biotechnology Association. In 2009, the province of British Columbia permanently endowed the Julia Levy B.C. Leadership Chair in Macular Research at the University of British Columbia (U.B.C.) in partnership with U.B.C. and QLT. 

About ProtoKinetix 

ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™). These molecules have been demonstrated to protect cells against hostile conditions that are present in all areas of transplantation including regenerative medicine. 

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that areforward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission. 

Clarence E. Smith –President and CEO 
Source: ProtoKinetix 

ProtoKinetix, Inc.Blair Henderson604-926-6627 

***PKTX.. PROTOKINETIX, INCORPORATED. 
9176 South Pleasants Highway 
St. Marys, WV 26170 
 

                                                                      ***ProtoKinetix Announces New President and Chief ExecutiveOfficer 
                                                                                                                     February 23, 2015 
...ProtoKinetix, Incorporated (OTC: PKTX) (www.protokinetix.com) (the "Company" or "ProtoKinetix") announces that a cease trade order issued by the British Columbia Securities Commission was revoked effective as of the date of this news release. 

..In connection with the revocation, the Company also announces that it has received and accepted the resignation of Mr. Ross Senior as a Director, President and Chief Executive Officer of the Company effective as of February 19, 2015. Mr. Clarence E. Smith has been appointed as the Company's new President and Chief Executive Officer. 

..ProtoKinetix further announces that it has moved its headoffice to 9176 South Pleasants Highway, St. Marys, West Virginia, USA 26170. 

About ProtoKinetix 

ProtoKinetix is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, theCompany is currently targeting the direct treatment of diseases that have a major inflammatory component. 
ON BEHALF OF THE BOARD OF DIRECTORS 
PROTOKINETIX, INCORPORATED 
Clarence E. Smith 
President and Chief Executive Officer 
For further information, please contact: 
Clarence E. Smith, President & Chief Executive Officer 
Telephone: 304-299-5070 
Email: csmith@protokinetix.com 


                                                               ***ProtoKinetix’ Summary of Their Glyco Peptide (AAGP™) Molecule Development  Tuesday
                                                                                                                   06/17/14
...Over 10-years ago, ProtoKinetix (PKTX) commissioned INSA (French National Institute of Applied Science) to produce a small, stable, synthetic glyco peptide using their gem diflouride platform. The molecule selected was a mimic of a well characterized, glyco protein known as Anti-Freeze Glyco Protein (AFGP). The lead scientist from INSA was Dr. Geraldine Deliencourt. 

..During this period of time ProtoKinetix was working of the molecule, a new medical initiative arose from theory to maturity through extensive research conducted on stem cells. This field of research is collectively known as “regenerative medicine”. Regenerative medicine attempts to replace damaged cells or tissues as an effective therapy for a wide range of diseases and conditions such as nerve damage, lung damage, heart damage, etc. ProtoKinetix’ role here is the protection of these cells before, during and after the procedure. 

..Under the terms of the original INSA commission, ProtoKinetix paid for the proof of concept in exchange for the worldwide exclusive rights to the family of AFGP molecules. Subsequently, ProtoKinetix has conducted extensive testing on cell preservation and anti-inflammation resulting in substantial data allowing the Company to file patents. To date, the patents have been granted for the United States, Europe and Canada. 

..In 2014, PKTX filed for a series of new patents based on results generated by the University of Alberta trials. These are brand new applications protected by worldwide provisional patents. 
The Company has completed a series of mechanism of action studies, showing how the molecule achieves its effect of inhibiting inflammation and protecting cells from premature death. This data will enable PKTX to more clearly identify the optimal therapeutic uses for disease. 

..Stem cell research has demonstrated major benefits of using AAGP™ during the following stages: 
1.      Freeze/thaw recovery (cryopreservation) 
2.      Primary differentiation 
3.      Migration to progenitor status (precursor cells) 
4.      Transplantation 
5.      Engraftment 
6.      Protection against anti-rejection drugs



                                ***ProtoKinetix Completes Sale of Exclusive Rights for AAGP™ Blood Preservation Applications 

VANCOUVER, British Columbia--(BUSINESS WIRE)-- March 5, 2014

ProtoKinetix (PKTX) (www.protokinetix.com) has announced the sale of one of the numerous cell protection applications that prove to significantly increase the shelf life of delicate cells and organs by the addition of AAGP™. The purchaser, Intrepid Innovations Corporation, is a wholly owned subsidiary of Umbra Applied Technologies Group (UATG) and has been funded to address the world-wide demand for blood product storage, and platelet preservation. 

Intrepid is completing this transaction with a combination of cash and securities totaling $2,500,000 USD to PKTX. This acquisition will enable Intrepid to complement their blood bag delivery system and further satisfy the growing domestic and international requirement for blood product trauma treatment. 
http://finance.yahoo.com/news/protokinetix-completes-sale-exclusive-rights-154800155.html 

                                                                                                                              
                                                                                                                   ***ProtoKinetix Sells Exclusive Rights to One of the Numerous AAGP™ Applications                              
Vancouver, British Columbia, April 1st, 2013
ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) has entered into the sale of exclusive rights to use it's AAGP™ molecule in all blood and blood platelet preservation applications. These rights have been sold to Intrepid Innovations Corporation for $2,500,000 USD after their extensive review of the AAGP™ molecule's ability to extend blood and blood platelet shelf life.
Intrepid Medical Technologies is a wholly own subsidiary of Intrepid Innovations Corporation that has been specifically funded to address the worldwide need for blood and blood platelet storage and preservation. Intrepid Medical (www.intrepidmedical.net) will be headed up by Mr. Tom Snyder. Tom is a graduate of Princeton University and Harvard Business School. Mr. Snyder brings financial and entrepreneurial experience to Intrepid Medical and has experience in blood diagnostics and therapeutics with Hyland Laboratories and Fenwal divisions of Baxter International.
This Agreement will serve as a blueprint for the commercialization of the numerous AAGP™ applications. The partnering format gives ProtoKinetix the flexibility to structure the sale of application rights to almost any qualified partner. This approach minimizes the cash requirement for product development and the fastest possible entry into the market.
About Intrepid
Intrepid Innovations Corporation is a diversified operation that has acquired, licensed or is developing a wide range of Intellectual Property Rights that offer the opportunity to integrate and commercialize these innovations on a global basis. These proprietary technologies range from wind power generation, oil and natural gas production, wood waste by-products to medical waste disposal and blood preservation.
About ProtoKinetix                
ProtoKinetix, Inc. is a molecular biotechnology company that has developed and patented a family of hyper stable, potent glycopeptides (AAGP™) that dramatically enhance the therapeutic results and reduce the cost of stem cell medicine. Due to the anti-inflammatory effect of AAGP™ molecules, the Company is currently targeting the direct treatment of diseases that have a major inflammatory component.

 
                   ***ProtoKinetix Forms Joint Venture Partnership to Launch a Dermatitis Therapeutic Product for the Skin Care Industry

Press Release Source: ProtoKinetix, Inc. On Wednesday April 27, 2011, 7:00 am EDT

VANCOUVER, British Columbia--(BUSINESS WIRE)-- ProtoKinetix (OTCBB:PKTX.ob - News) (www.protokinetix.com), is pleased to announce, that it has entered into a Joint Venture Agreement with Imaginative Research Associates, Inc. to formulate a topical anti-inflammation product for the skin care market. Over the last 23-years Imaginative Research Associates, Inc. has successfully partnered with several large pharmaceutical dermatology and cosmetic companies and has licensed out patents and know-how to launch many leading products in the skin care arena. Naomi Vishnupad, Ph.D., is the President and COO of this Massachusetts based firm and has over 10-years of experience in the pharmaceutical industry in all areas of drug development. She has held positions in both big pharma, such as Wyeth Pharmaceuticals and Bristol-Myers Squibb, and small biotech companies. Naomi holds a Ph.D. and M.S. in immunology and a B.S. in biology.

Upon completion of this formulation, the Joint Venture will be able to offer a topical preparation to specifically address skin conditions caused by inflammation. Conditions such as dermatitis, psoriasis and eczema are often treated with applications of corticosteroids or immune modulators, both of which carry inherent, long term health risks. ProtoKinetix' AAGP™ has consistently demonstrated powerful anti-inflammatory properties without toxic side effects. The formulation and development of this therapeutic product line will offer hope for an effective prescription and over the counter preparations to combat these chronic inflammation causing diseases, while eliminating potential risks from many of the current front line treatments. 

 

ProtoKinetix Receives Excellent Results from the University of British Columbia Eye Inflammation Study
PRESS RELEASE >> September 21 - 2011

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com), is pleased to announce that it has received excellent results from the eye inflammation study conducted by UBC (University of British Columbia). The tests conducted by Dr. Gregory-Evans MD, PhD, FRCS, FRCOphth, were designed to determine whether the powerful anti-inflammatory AAGP™ molecule could be successfully delivered to inflamed areas throughout the eye. The result demonstrated that AAGP™ penetrates through the extremely protective barriers of the eye without side effects.

ProtoKinetix has proven the ability of AAGP™ to protect human cells against inflammation causing agents. There are many forms of eye inflammation that are typically treated with an aggressive course of corticosteroids. Due, in part, to the short effective life of topical steroids, current treatments involve the application on an hourly basis. These powerful drugs can lead to numerous sight threatening complications.

Dr. Gregory-Evans, a professor of Ophthalmology and Leadership Chair in Macular Research, concludes that AAGP™ penetrates the eye when topically applied as a twice a day or four times a day regimen. AAGP™ can be detected within the cornea and ciliary body. Drug was also seen to appear in retinal tissue, most convincingly when a four times a day regimen was used.

These results represent a major step in the development of a potent, non-steroidal, anti-inflammatory drug.

Italian Laboratory Expands ProtoKinetix' Market for AAGP™
PRESS RELEASE >> December 07 - 2011
 

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com) is pleased to announce results from Areta International laboratory in Italy. These results show dramatic increases in the production of monoclonal antibodies when AAGP™ is incorporated into the production cycle. Monoclonal antibodies are one of the fastest growing sectors of the pharmaceutical industry. This market is presently over $50-billion USD per year and growing rapidly. As a therapeutic, monoclonal antibodies do not cause the same side-effects of chemotherapy and radiation treatment.

Since the Company continues to focus on the anti-inflammation applications of AAGP™, they intend to partner the monoclonal antibody development to pharmaceutical laboratories. Monoclonal antibodies have proven themselves to be highly effective therapies and diagnostics, in a growing list of diseases. Access to this class of drug is extremely restricted, due to the prohibitive cost. In order for monoclonal antibodies to be universally available, the cost has to be aggressively reduced.

Initial results from these tests demonstrate a 300% to 500% increase in monoclonal antibody production in the presence of AAGP™. This significant increase in yield, will result in major cost reductions for the treatment of cardio vascular disease, auto-immune disorders, leukemia, transplant rejection, cancer as well as numerous diagnostics.






 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PKTX
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PKTX News: Statement of Changes in Beneficial Ownership (4) 09/23/2016 06:10:39 PM
PKTX News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/19/2016 05:09:56 PM
PKTX News: Statement of Changes in Beneficial Ownership (4) 09/19/2016 05:04:19 PM
PKTX News: Small Company Offering and Sale of Securities Without Registration (d) 09/16/2016 04:19:44 PM
PKTX News: Statement of Changes in Beneficial Ownership (4) 09/09/2016 04:29:55 PM
PostSubject
#1641  Sticky Note ProtoKinetix Patents: Past and present 03/09/14 03:20:27 PM
#2521   The TBRA stock going from $5 to $40 PK holder 09/28/16 09:47:34 AM
#2520   Market makers could be caught short here if PK holder 09/27/16 02:58:53 PM
#2519   Also I believe if anyone wants this company Brando1975 09/26/16 09:11:16 PM
#2518   ***PKTX.. If Tobira ticker symbol TBRA recently Past and present 09/26/16 08:23:00 PM
#2516   PKTX friends, what does new ownership mean for Basilica 09/26/16 07:23:24 PM
#2515   I really think we have been doing good Brando1975 09/26/16 06:08:08 PM
#2514   Stuck PK holder 09/26/16 01:39:45 PM
#2513   Until we breakthrough this 6 cent level. We PK holder 09/26/16 01:39:14 PM
#2512   PKTX News: Statement of Changes in Beneficial Ownership mick 09/24/16 12:34:58 PM
#2511   thank you heads up chat/ pktx mick 09/24/16 12:34:47 PM
#2510   We will 100% close up today! I feel Brando1975 09/23/16 01:27:16 PM
#2509   The psychology of this stock is the 5-6 PK holder 09/23/16 10:33:55 AM
#2508   Let's see if we can reach new highs PK holder 09/22/16 03:29:51 PM
#2507   pktx..im just sitting back watching..and not worrying on acc724 09/22/16 02:04:53 PM
#2506   $PKTX One Month Chart http://www.stockscores. $Pistol Pete$ 09/22/16 01:07:21 PM
#2505   PKTX looks to have something up their sleeve! ListenToMe 09/22/16 10:12:11 AM
#2504   When the application to Health Canada is made PK holder 09/22/16 09:23:40 AM
#2503   ***PKTX.. Thanks PK holder.. Great information.. Past and present 09/21/16 12:44:08 PM
#2502   Stock acting great, seems we might have a PK holder 09/21/16 11:51:34 AM
#2501   Another HUGE volume day!! We need to close Brando1975 09/21/16 11:49:34 AM
#2500   Im so happy I accidentally found this company. Brando1975 09/20/16 04:31:30 PM
#2499   ***PKTX..We(PKTX)"BE" Looking Good.. To the Moon..Alice..! Past and present 09/20/16 03:40:19 PM
#2498   If I was another investor who owned, I Brando1975 09/19/16 11:39:39 PM
#2497   Seems to me if you're telling people you PK holder 09/19/16 10:50:53 PM
#2496   Ok dude. Just trying to make cash like Brando1975 09/19/16 06:19:19 PM
#2495   Who cares dude....get off your high horse..no one floydborga 09/19/16 06:15:11 PM
#2494   Let me make this extremely clear to everyone. Brando1975 09/19/16 05:06:31 PM
#2493   Well said for sure!!! Brando1975 09/18/16 09:32:41 PM
#2492   ***PKTX...Dear Brando... New Re-Engineered Company, New Management Team, Past and present 09/18/16 08:06:11 PM
#2491   Thank you for the information. I am just Brando1975 09/18/16 06:37:07 PM
#2490   There a multiple reasons. Stigma of being a PK holder 09/18/16 03:10:42 PM
#2489   Would you be willing to share the information? Brando1975 09/18/16 02:59:49 PM
#2488   Yes I know why. PK holder 09/18/16 01:40:58 PM
#2487   I follow what you're saying. I understand the Brando1975 09/18/16 01:39:36 PM
#2486   Market makers do not own shares. That's a PK holder 09/18/16 08:44:01 AM
#2485   If CSMITH believes in pktx enough to buy Brando1975 09/17/16 03:05:05 PM
#2484   If this stays under 6c for a week Brando1975 09/17/16 12:30:51 PM
#2483   Next two week a group of friends and Brando1975 09/17/16 12:04:09 PM
#2482   This kind of volume and not closing green PK holder 09/16/16 03:45:56 PM
#2481   Until next week lets not worry about price Brando1975 09/16/16 02:45:15 PM
#2480   I really wanted to throw a big order Brando1975 09/16/16 02:19:19 PM
#2479   I have a sick daughter today but can Brando1975 09/16/16 02:18:06 PM
#2478   This has to get over 6 cents to PK holder 09/16/16 02:12:23 PM
#2477   I plan on buying the .0575 order for Brando1975 09/16/16 01:31:01 PM
#2476   I was very serious about the tshirts being Brando1975 09/16/16 12:24:26 PM
#2475   Just another fun day! Its gonna keep on Brando1975 09/16/16 12:21:22 PM
#2474   Lets plan on another big day!! Brando1975 09/16/16 09:58:03 AM
#2473   Im only trying to spread the news and Brando1975 09/16/16 09:30:08 AM
#2472   You don't BS the fun has begun soak livemint 09/16/16 06:17:08 AM
#2471   Does everyone one know what happens if you Brando1975 09/16/16 12:08:00 AM
PostSubject